Penumbra Inc (PEN)
Just a little further up the 2019 gains ladder, is medical device maker Penumbra. Specializing in innovative neuro and peripheral vascular therapies, PEN is seeing out the year with a 33% increase to its share price.
A technology leader in mechanical thrombectomy, the company’s two lead products, the Penumbra System (neurovascular) and the Indigo System (peripheral vascular), both remove blood clots, and are in a large and unpenetrated market, estimated to be worth roughly $3.1 billion.
Penumbra has a massive market to address in the treatment of ischemic strokes, too, believed by the company to be worth $7 billion worldwide, and $0.8 billion in the US alone. In July, PEN released its most advanced technology to date – the Penumbra JET 7 Reperfusion Catheter, which is to be used with the Penumbra ENGINE, a system that allows physicians to extract thrombus in acute ischemic stroke patients.
RBC’s Brandon Henry believes PEN’s systems are “superior to the competition.” The analyst noted, “Our model assumes that PEN will grow its revenues in the high teens over the next three years. We assume that it will have low salesforce turnover and continue to innovate its existing product lines, particularly JET-ENGINE and the Indigo System. Additionally, we assume that PEN’s Peripheral Vascular segments will grow more quickly than the market, as the company continues to take share despite competition.”Therefore, Henry kept an Outperform rating on Pen, along with a target price of $192, implying potential upside of 18%.